SCHEMBL330167

SCHEMBL330167

C/C=C/C=C/C=C/COC(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 2/20 0.46
TK1 P04183 1/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
AKT1 P31749 1/20 0.41
F2 P00734 1/20 0.41
CYP3A4 P08684 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330168 1.00 LMNA (0.49) LMNATDP1TSHRTK1MAPK1
SCHEMBL18204470 0.98 LMNA (0.50) LMNATDP1TSHRTK1MAPK1
SCHEMBL15978100 0.98 LMNA (0.50) LMNATDP1TSHRTK1MAPK1
SCHEMBL2434556 0.86 LMNA (0.55) LMNATDP1TSHRTK1MAPK1
SCHEMBL15450091 0.86 LMNA (0.55) LMNATDP1TSHRTK1MAPK1
SCHEMBL15869135 0.86 LMNA (0.55) LMNATDP1TSHRTK1MAPK1
SCHEMBL7867427 0.84 ESR1 (0.54) LMNATDP1TSHRMAPK1SLC6A2
SCHEMBL19810157 0.83 LMNA (0.56) LMNATDP1TSHRMAPK1HIF1A
SCHEMBL19810156 0.83 LMNA (0.56) LMNATDP1TSHRMAPK1HIF1A
SCHEMBL19810158 0.83 LMNA (0.56) LMNATDP1TSHRMAPK1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3041459-B1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI SPA (IT) 2019-04-03 EP claimed
EP-2593097-B1 COMPOUNDS WITH A SKIN PIGMENTING ACTIVITY AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS CONTAINING THEM GIULIANI SPA (IT) 2016-08-24 EP claimed
EP-3041459-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER Giuliani S.p.A. (IT) 2016-07-13 EP claimed
WO-2015033276-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI S.P.A. (IT) 2015-03-12 WO claimed
EP-2593097-A1 COMPOUNDS WITH A SKIN PIGMENTING ACTIVITY AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS CONTAINING THEM Giuliani S.p.A. (IT) 2013-05-22 EP claimed
US-20130108564-A1 Compounds with a Skin Pigmenting Activity And Pharmaceutical or Cosmetic Compositions Containing Them GIULIANI S.P.A. (IT) 2013-05-02 US claimed
WO-2012007572-A1 COMPOUNDS WITH A SKIN PIGMENTING ACTIVITY AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS CONTAINING THEM GIULIANI S.P.A. (IT) 2012-01-19 WO claimed
EP-2407163-A1 Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them Giuliani S.p.A. (IT) 2012-01-18 EP claimed
EP-3041459-B1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI SPA (IT) 2019-04-03 EP disclosed
EP-2593097-B1 COMPOUNDS WITH A SKIN PIGMENTING ACTIVITY AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS CONTAINING THEM GIULIANI SPA (IT) 2016-08-24 EP disclosed
US-20160213635-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI S.P.A. (IT) 2016-07-28 US disclosed
US-20160213635-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI S.P.A. (IT) 2016-07-28 US disclosed
US-9192595-B2 Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them GIULIANI S.P.A. (IT) 2015-11-24 US disclosed
US-9192595-B2 Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them GIULIANI S.P.A. (IT) 2015-11-24 US disclosed
WO-2015033276-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER GIULIANI S.P.A. (IT) 2015-03-12 WO disclosed
US-20130108564-A1 Compounds with a Skin Pigmenting Activity And Pharmaceutical or Cosmetic Compositions Containing Them GIULIANI S.P.A. (IT) 2013-05-02 US disclosed
US-20130108564-A1 Compounds with a Skin Pigmenting Activity And Pharmaceutical or Cosmetic Compositions Containing Them GIULIANI S.P.A. (IT) 2013-05-02 US disclosed
WO-2012007572-A1 COMPOUNDS WITH A SKIN PIGMENTING ACTIVITY AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS CONTAINING THEM GIULIANI S.P.A. (IT) 2012-01-19 WO disclosed
EP-2407163-A1 Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them Giuliani S.p.A. (IT) 2012-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213635-A1 COMPOSITIONS USEFUL IN THE PREVENTION OR TREATMENT OF SKIN CANCER PKLR, AKR1C3, HK1 LMNA 105/4885TDP1 1985/4885TSHR 3804/4885
US-20130108564-A1 Compounds with a Skin Pigmenting Activity And Pharmaceutical or Cosmetic Compositions Containing Them TYR, MC1R, HK1 LMNA 1303/4885TDP1 4174/4885TSHR 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.